WO2021096314A1 - Nouveau dérivé de benzimidazole et son utilisation - Google Patents

Nouveau dérivé de benzimidazole et son utilisation Download PDF

Info

Publication number
WO2021096314A1
WO2021096314A1 PCT/KR2020/016038 KR2020016038W WO2021096314A1 WO 2021096314 A1 WO2021096314 A1 WO 2021096314A1 KR 2020016038 W KR2020016038 W KR 2020016038W WO 2021096314 A1 WO2021096314 A1 WO 2021096314A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzo
imidazol
piperidine
carboxamide
mmol
Prior art date
Application number
PCT/KR2020/016038
Other languages
English (en)
Korean (ko)
Inventor
서승용
김선여
맹한주
이재혁
이산하
이빛
이정은
Original Assignee
가천대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가천대학교 산학협력단 filed Critical 가천대학교 산학협력단
Publication of WO2021096314A1 publication Critical patent/WO2021096314A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés à base de benzimidazole et leurs utilisations. Les nouveaux composés à base de benzimidazole selon la présente invention inhibent la formation de produits finis de glycation avancée (AGE), et peuvent donc être utiles dans la prévention ou le traitement de maladies provoquées par des AGE.
PCT/KR2020/016038 2019-11-15 2020-11-13 Nouveau dérivé de benzimidazole et son utilisation WO2021096314A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0146784 2019-11-15
KR20190146784 2019-11-15

Publications (1)

Publication Number Publication Date
WO2021096314A1 true WO2021096314A1 (fr) 2021-05-20

Family

ID=75913115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/016038 WO2021096314A1 (fr) 2019-11-15 2020-11-13 Nouveau dérivé de benzimidazole et son utilisation

Country Status (2)

Country Link
KR (1) KR20210059663A (fr)
WO (1) WO2021096314A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153701A1 (fr) * 2007-05-24 2008-12-18 Schering Corporation Composés d'inhibition de l'activité de ksp kinésine
WO2014096388A2 (fr) * 2012-12-21 2014-06-26 Selvita S.A. Nouveaux dérivés de benzimidazole en tant qu'inhibiteurs de la kinase
WO2017040993A1 (fr) * 2015-09-03 2017-03-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Petites molécules inhibitrices de dyrk1a et leurs utilisations
WO2017143011A1 (fr) * 2016-02-16 2017-08-24 Chrysalis, Inc. Inhibiteurs d'histones déméthylases
WO2017144909A1 (fr) * 2016-02-25 2017-08-31 Gesynta Pharma Ab Méthodes de traitement de maladies caractérisées par une vasoconstriction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180024825A (ko) 2016-08-31 2018-03-08 엘지디스플레이 주식회사 표시 장치 및 표시 장치 구동 방법
KR101899234B1 (ko) 2017-01-12 2018-09-17 가천대학교 산학협력단 전나무 메탄올 추출물, 이의 분획물 또는 이들로부터 분리한 화합물을 포함하는 최종당화산물 관련 질환의 예방 또는 치료용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153701A1 (fr) * 2007-05-24 2008-12-18 Schering Corporation Composés d'inhibition de l'activité de ksp kinésine
WO2014096388A2 (fr) * 2012-12-21 2014-06-26 Selvita S.A. Nouveaux dérivés de benzimidazole en tant qu'inhibiteurs de la kinase
WO2017040993A1 (fr) * 2015-09-03 2017-03-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Petites molécules inhibitrices de dyrk1a et leurs utilisations
WO2017143011A1 (fr) * 2016-02-16 2017-08-24 Chrysalis, Inc. Inhibiteurs d'histones déméthylases
WO2017144909A1 (fr) * 2016-02-25 2017-08-31 Gesynta Pharma Ab Méthodes de traitement de maladies caractérisées par une vasoconstriction

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
US11944622B2 (en) 2018-10-05 2024-04-02 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Also Published As

Publication number Publication date
KR20210059663A (ko) 2021-05-25

Similar Documents

Publication Publication Date Title
WO2011043568A2 (fr) Nouveaux composés efficaces comme inhibiteurs de la xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant
WO2016032120A1 (fr) Nouveau dérivé d'amino-phényl-sulfonyl-acétate et son utilisation
WO2021187886A1 (fr) Agoniste du récepteur glp-1, composition pharmaceutique le comprenant et son procédé de préparation
WO2021118318A2 (fr) Nouveau dérivé d'indole et son utilisation
WO2021066608A1 (fr) Composé destiné à induire l'expression d'un gène klotho anti-âge et son utilisation
WO2016080810A2 (fr) Composé de biguanide et utilisation de celui-ci
AU2019310508B2 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
WO2017018751A1 (fr) Nouveau composé présentant une activité inhibitrice de blt et composition, destiné à prévenir ou à traiter des maladies inflammatoires, contenant ce dernier en tant que principe actif
WO2018062978A1 (fr) Nouveau composé hétéroaryle, énantiomère, diastéréoisomère ou sel pharmaceutiquement acceptable de celui-ci, et composition antivirale le contenant en tant que principe actif
WO2021096314A1 (fr) Nouveau dérivé de benzimidazole et son utilisation
WO2013105753A1 (fr) Dérivés de pipéridine substituée et procédés pour les préparer
WO2013043002A1 (fr) Dérivé de benzothiazole contenant imide ou son sel et composition pharmaceutique le comprenant
WO2011122815A2 (fr) Nouveaux dérivés de quinoxaline
WO2015060613A1 (fr) Nouveau dérivé oxodihydropyridinecarbohydrazide antifongique
WO2018008989A1 (fr) Dérivé de benzo[d]thiazole ou sel de celui-ci et composition pharmaceutique le comprenant
WO2016006975A2 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
WO2009093872A2 (fr) Nouveau composé d'hydrazine ou ses sels pharmaceutiquement acceptables, procédé de préparation associé, et composition pharmaceutique utilisée pour traiter le cancer et contenant le composé
WO2012148140A2 (fr) Dérivés d'alcaloïdes à base d'imidazole ayant des effets d'inhibition de l'angiogenèse et antioxydants et leur procédé de préparation
WO2010032986A2 (fr) Nouveaux dérivés de 5-(4-aminophenyl)-isoquinoline, leurs sels pharmaceutiquement acceptables, procédé de production associé et composition contenant les dérivés comme principe actif pour la prophylaxie et le traitement d'états pathologiques induits par l'hyperactivité de la kinase raf
WO2017217741A1 (fr) Nouveau dérivé de furanone bromé, son procédé de préparation, et composition pharmaceutique comprenant le nouveau dérivé de furanone bromé en tant que principe actif
WO2022050749A1 (fr) Nouveau dérivé biaryle utile en tant qu'inhibiteur de la diacylglycérol acyltransférase 2, et son utilisation
WO2021125905A1 (fr) Nouveau dérivé thiazole et son utilisation
WO2023132681A1 (fr) Composition pharmaceutique et composition alimentaire comprenant de la 1-alkyl-5-arylidène-2-sélénoxoimidazolidin-4-one et un dérivé de celle-ci pour la prévention, le soulagement ou le traitement d'une maladie inflammatoire
WO2022010328A1 (fr) 1-alkyl-5-arylidène-2-sélénooxoimidazolidine-4-one et son dérivé, son procédé de préparation et composition le comprenant pour prévenir, soulager ou traiter des maladies neurodégénératives
WO2022119090A1 (fr) Dérivés de biphénylpyrrolidine et de biphényldihydroimidazole permettant d'inhiber l'activité du récepteur 5-ht7 de la sérotonine, et composition pharmaceutique le comprenant comme principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20886767

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20886767

Country of ref document: EP

Kind code of ref document: A1